{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-039764","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.798481+00:00","generated_at":"2026-06-17T07:43:28.577233+00:00","sec_items":["2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone Pharma raises $50M in convertible notes and $75M contingent royalty sale","bullets":["Issued $50M principal of 6.0% Convertible Senior Notes due 2029 to RTW Investments.","Notes convertible at ~$5.23 per share (191.0548 shares per $1,000 principal).","Interest payable quarterly; PIK option for first 3 years; secured by substantially all assets.","Royalty Purchase Agreement: RTW to pay $75M for tiered royalties on U.S. etripamil sales post-FDA approval.","Proceeds support development of etripamil; notes mature March 31, 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-039764","json":"https://secwatch.observer/filing/0001104659-23-039764.json","markdown":"https://secwatch.observer/filing/0001104659-23-039764.md","text":"https://secwatch.observer/filing/0001104659-23-039764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/0001104659-23-039764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/tm2311047d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:43:28.577233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5179cfb0e2ecbe615cc442352f917e1f3cdc5d3e","claim":"Milestone Pharmaceuticals Inc. incurred senior notes of $50 million principal amount with RTW Investments, LP and certain of its affiliates at 6.0% maturing March 31, 2029.","evidence_excerpt":"On March 29, 2023, the Company closed the transaction contemplated by the Note Purchase Agreement and issued and sold the $50 million principal amount of 6.0% Convertible Senior Notes due 2029","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/0001104659-23-039764-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$50 million principal amount"},{"label":"Counterparty","value":"RTW Investments, LP and certain of its affiliates"},{"label":"Rate","value":"6.0%"},{"label":"Maturity","value":"March 31, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ecdc2b5bd9909d6e6cc559994612ca20ab1bb6d1","claim":"Milestone Pharmaceuticals Inc. incurred debt of $75.0 million with RTW Investments, LP and certain of its affiliates at tiered quarterly royalty payments.","evidence_excerpt":"nd a Note Purchase Agreement (the “Note Purchase Agreement”) with RTW Investments, LP and certain of its affiliates (collectively, “RTW”). Royalty Purchase Agreement Pursuant to the Royalty Purchase Agreement, RTW","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/0001104659-23-039764-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"$75.0 million"},{"label":"Counterparty","value":"RTW Investments, LP and certain of its affiliates"},{"label":"Rate","value":"tiered quarterly royalty payments"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}